Incannex reports Q2 EPS (33c) vs (33c) last year

Reports Q2 revenue $12,000. “Patients with obstructive sleep apnea need new and convenient therapeutic options to manage this serious, chronic and life-threatening disease. We are enthusiastic about the potential for IHL-42X, an oral, once-daily treatment that uniquely targets physiological pathways responsible for the airway obstruction characteristic of OSA. We achieved a key milestone for our OSA program, reporting positive top-line results from a pharmacokinetics (PK) and safety study of IHL-42X, conducted alongside our global Phase 2/3 RePOSA study,” said Joel Latham, Incannex’s (IXHL) President and Chief Executive Officer.